Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

被引：0
|
作者：
Mikkel Krogh-Madsen
Brendan Bender
Morten Krogh Jensen
Ove Juul Nielsen
Lena E. Friberg
Per Hartvig Honoré
机构：
[1] University of Copenhagen,Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences
[2] Uppsala University,Department of Pharmaceutical Biosciences, Pharmacometrics Research Group
[3] Herlev Hospital,Department of Haematology L
[4] Rigshospitalet,124
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Cytarabine; Etoposide; Daunorubicin; Population pharmacokinetics; NONMEM; Acute myeloid leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1155 / 1163
页数：8
相关论文
共 50 条
  • [1] Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
    Krogh-Madsen, Mikkel
    Bender, Brendan
    Jensen, Morten Krogh
    Nielsen, Ove Juul
    Friberg, Lena E.
    Honore, Per Hartvig
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1155 - 1163
  • [2] Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
    Murphy, Tracy
    Yee, Karen W. L.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1765 - 1780
  • [3] Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia
    Savitha Varatharajan
    John C. Panetta
    Ajay Abraham
    Sreeja Karathedath
    Ezhilpavai Mohanan
    Kavitha M. Lakshmi
    Nancy Arthur
    Vivi M. Srivastava
    Sandeep Nemani
    Biju George
    Alok Srivastava
    Vikram Mathews
    Poonkuzhali Balasubramanian
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 78 : 1051 - 1058
  • [4] Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia
    Varatharajan, Savitha
    Panetta, John C.
    Abraham, Ajay
    Karathedath, Sreeja
    Mohanan, Ezhilpavai
    Lakshmi, Kavitha M.
    Arthur, Nancy
    Srivastava, Vivi M.
    Nemani, Sandeep
    George, Biju
    Srivastava, Alok
    Mathews, Vikram
    Balasubramanian, Poonkuzhali
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (05) : 1051 - 1058
  • [5] Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
    Ronson, Aaron
    Tvito, Ariella
    Rowe, Jacob M.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 369 - 374
  • [6] AMSACRINE, CYTARABINE AND ETOPOSIDE IN THE TREATMENT OF BAD PROGNOSIS ACUTE MYELOID-LEUKEMIA
    WAHLIN, A
    [J]. MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1989, 6 (03): : 199 - 205
  • [7] Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients ≥60 years (CALGB 9720)
    Baer, Maria R.
    George, Stephen L.
    Sanford, Ben L.
    Bothun, Sandra M.
    Mrozek, Krzysztof
    O'Loughlin, Kieran L.
    Kolitz, Jonathan E.
    Moore, Joseph O.
    Stone, Richard M.
    Powell, Bayard L.
    Caligiuri, Michael A.
    Bloomfield, Clara D.
    Larson, Richard A.
    [J]. BLOOD, 2007, 110 (11) : 94A - 94A
  • [8] Daunorubicin for the treatment of acute myeloid leukemia
    Bertuzzi, Clara
    Paolini, Stefania
    Visani, Giuseppe
    Piccaluga, Pier Paolo
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1075 - 1087
  • [9] Infusional etoposide, daunorubicin, vincristine, and cytarabine in relapsed acute myelogenous leukemia.
    Walker, B
    Elkins, S
    Bigelow, C
    Files, J
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S289 - S289
  • [10] Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia
    Zhong, Sharon
    Kurish, Heena
    Walchack, Robert
    Li, Hong
    Edwards, Jessi
    Singh, Abhay
    Advani, Anjali
    [J]. LEUKEMIA RESEARCH, 2024, 139
12345